With the increased use of direct-activity oral anticoagulants (DOACs) over the last decade, it is inevitable that emergency departments are seeing more patients with DOAC-related bleeding. Get an inside look at pharmacists’ strategies for optimizing reversal of DOAC-related bleeding in various ED settings.
SPEAKERS
James S. Kalus, Pharm.D, FASHP, is Director of Pharmacy at Henry Ford Health System in Detroit, Michigan. He also is Program Director for the PGY1 residency at Henry Ford Hospital and adjunct assistant professor of pharmacy and medicine at Wayne State University. Dr. Kalus earned his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees at the University of Toledo in Toledo, Ohio, and completed a residency and two-year cardiovascular research fellowship. His research has focused on cardiovascular disease, and he serves on the editorial board of Annals of Pharmacotherapy, Cardiology Panel. He recently completed an appointment to the ASHP Commission on Credentialing.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company.
Darius J. Faison, Pharm.D., BCPS, is an emergency medicine clinical specialist at Henry Ford Wyandotte Hospital in Wyandotte, Michigan, where he also serves as a PGY1 residency preceptor for the emergency medicine rotation. His current practice initiatives include designing and implementing an ED-specific sedation and analgesia protocol for mechanically ventilated patients, improving anticoagulation reversal processes in the ED, and enhancing interprofessional ED sepsis management. Dr. Faison earned his Doctor of Pharmacy degree from the University of Florida College of Pharmacy in Gainesville and completed a PGY1 residency at Henry Ford Hospital. He is an active member of ASHP and ACCP.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company.
All others in control of the content of this activity do not have a relevant financial relationship (RFR) with an ineligible company.
This podcast is provided by ASHP and supported by an educational grant from Alexion Pharmaceuticals, Inc.
